Minoxidil
A drug that was supposed to treat high blood pressure and instead became the longest-running over-the-counter hair-loss treatment in the world — discovered by accident, working through a completely different mechanism than finasteride, with one of the longest clinical-trial track records in dermatology.
Number of studies
4
Safety
Requires caution
Time to effects
The temporary shedding phase can appear as early as weeks 2-8 of treatment. The first visible signs of regrowth usually appear after 3-4 months of consistent use, with a fully assessable clinical effect after 6-12 months of uninterrupted treatment. The effect requires indefinite continuation; it fades within a few months of stopping.
Monthly cost
ok. 35-90 zł/miesiąc dla formy miejscowej; forma doustna (receptura) zwykle wychodzi wyraźnie taniej, ale wymaga recepty i wizyty lekarskiej
Price in Poland
35-90 zł za opakowanie formy miejscowej starczające na miesiąc stosowania (cena zależy od koncentracji, formy i producenta — generyki są tańsze niż marki oryginalne)
Who it's for
Forma miejscowa jest w Polsce dostępna bez recepty w aptekach i dużych sieciach drogeryjnych. Forma doustna w leczeniu łysienia nie ma zarejestrowanego, fabrycznego preparatu w tym wskazaniu — przygotowywana jest w aptekach recepturowych na podstawie recepty lekarskiej.
Indicative prices for the Polish market — we don't point to specific retailers; the real price depends on the manufacturer, form and place of purchase.
Table of contents
TL;DR
A drug that was supposed to treat high blood pressure and instead became the longest-running over-the-counter hair-loss treatment in the world — discovered by accident, working through a completely different mechanism than finasteride, with one of the longest clinical-trial track records in dermatology.
- →Efficacy documented in numerous RCTs for both male androgenetic alopecia and female pattern hair loss (FPHL)
- →DHT-independent mechanism — doesn't affect libido, erection, or androgen hormone levels, unlike finasteride or dutasteride
- →Available over the counter in topical form in Poland, with no doctor visit required before starting basic treatment
| Drug class | Piperidinopyrimidine derivative; opens ATP-sensitive potassium (K_ATP) channels |
|---|---|
| Mechanism | Vasodilation + anagen-phase prolongation + improved hair follicle cell survival |
| Available forms | 2% and 5% topical solution/foam; oral tablets (off-label, low dose) |
| Status | Topical form — over the counter; oral form for this indication — compounded prescription only |
| Evidence level | Strong — one of the longest and most extensively studied hair-loss treatments (since the 1980s) |
| DHT dependence | None — works independently of the testosterone-DHT axis, unlike finasteride/dutasteride |
| Need for continued use | Yes — the effect is fully reversible and fades within a few months of stopping |
Understand
Overview
Minoxidil is one of those rare cases in pharmacology where a drug developed for one condition turned out to be even more useful for a completely different, unplanned indication. Developed in the 1970s by Upjohn as an oral vasodilator for severe, treatment-resistant hypertension, minoxidil quickly drew attention for a striking, unintended side effect: in a large share of patients it caused excessive hair growth across the body (hypertrichosis). That observational discovery — not a planned hair-loss trial — is what launched the entire category of topical and oral anti-hair-loss treatments we have today.
Today minoxidil exists in two quite different forms worth distinguishing right away. The topical form — a solution or foam applied to the scalp — is available over the counter in Poland and most other countries, and remains the primary, best-studied way the drug is used for hair loss. The oral form, at very low doses (known in the literature as LDOM, low-dose oral minoxidil), is a newer, fast-growing trend — still formally off-label for this indication, requiring a prescription and medical oversight, but backed by a steadily growing evidence base on efficacy and safety, which we cover in more depth in a separate article comparing the two forms.
Understanding minoxidil's place in hair-loss treatment hinges on one key fact: it works through a completely different mechanism than finasteride and dutasteride, which we cover in our article on 5-alpha-reductase inhibitors. Those drugs block the conversion of testosterone into DHT, the hormone responsible for follicle miniaturization in androgenetic alopecia. Minoxidil doesn't touch that hormonal pathway at all — it acts at the level of the follicle itself and its blood supply, independent of DHT levels. That's why the two drugs don't compete with each other but rather complement one another, and why minoxidil is the only thoroughly studied pharmacological option for women, for whom finasteride isn't standard practice due to teratogenic risk and more limited efficacy in this group.
Minoxidil's evidence base is unusually broad by cosmetic dermatology standards — it spans dozens of placebo-controlled randomized trials conducted from the late 1980s to the present, in both men and women, across different concentrations and formulations. It's rare for an over-the-counter drug to have such a long, consistent history of confirmed efficacy under controlled conditions, rather than studies funded solely by a single manufacturer.
In recent years, the most dynamically growing area has been exactly this low-dose oral minoxidil — driven partly by publications from academic centers (Mayo Clinic, universities in Brazil and Australia), and partly by rising popularity on social media and hair-loss forums. It's a good example of clinical practice outrunning a drug's formal approval for a new indication: more and more dermatologists are prescribing LDOM off-label, armed with real, if still growing, safety data rather than just anecdotal user reports.
It's worth having realistic expectations: minoxidil, in either form, is not a drug that revives already completely lost, scarred follicles, and it doesn't replace a hair transplant in advanced hair loss. It works best where follicles still exist but are miniaturized — that is, in early to moderate stages of androgenetic alopecia and female pattern hair loss. That distinction — "slowing down and partially reversing," not "full regeneration" — is the key to setting realistic expectations before starting treatment.
History of use
Minoxidil was developed in Upjohn's labs in the 1960s and 1970s as a potent oral vasodilator for severe hypertension resistant to other treatments — marketed as Loniten, it was approved in the US in 1979. Doctors quickly noticed a pronounced, unintended hypertrichosis in patients taking the drug, prompting Upjohn researchers to test a topical formulation specifically for hair loss. After a series of clinical trials, the FDA approved a 2% topical solution in 1988 as the first-ever over-the-counter hair-loss drug, initially for men only, extending to women in 1991. A stronger 5% formulation was approved for men in 1997, showing clearly better results in head-to-head trials. Over the last decade, driven partly by work from Australian dermatologist Rodney Sinclair and teams at Mayo Clinic, interest in very-low-dose oral minoxidil (LDOM) has surged as an alternative for people who can't tolerate or don't respond to the topical form — a practice that remains formally outside the drug's approved indication but is increasingly accepted clinically.
Mechanism of action
Minoxidil itself is a prodrug — only after conversion by the enzyme sulfotransferase (mainly the SULT1A1 isoform) present in hair follicles and the liver does its active metabolite, minoxidil sulfate, form. It's this metabolite that opens ATP-sensitive potassium channels in vascular smooth muscle cells and hair follicle cells, causing cell membrane hyperpolarization and vasodilation. Widening the small vessels in the scalp increases blood, oxygen, and nutrient supply to hair follicles, which is often described as the drug's main — though not its only — mechanism of action. It's worth stressing: this mechanism is fundamentally different from finasteride's, which lowers DHT — minoxidil doesn't meaningfully affect androgenic hormones and works independently of the testosterone-DHT axis, making it complementary to, rather than competing with, 5-alpha-reductase inhibitors.
Sulfotransferase enzyme activity varies considerably between individuals — one reason minoxidil 'doesn't work' as well for some users as for others. Low SULT1A1 activity in the follicle means less conversion to the active drug form, and some trichology clinics now offer tests measuring this enzyme's activity (e.g. on a sample of plucked hairs) as a way to predict treatment response, though the method isn't yet widely validated in large studies.
Beyond vasodilation, minoxidil also acts directly on follicle cells through several signaling pathways. It activates ERK (extracellular signal-regulated kinase) and the Akt pathway, promoting survival of dermal papilla cells — the structure that regulates the hair growth cycle. It also raises the ratio of anti-apoptotic to pro-apoptotic proteins (Bcl-2 to Bax), reducing premature follicle cell death and delaying the transition from anagen (growth) to catagen (regression). The drug also increases vascular endothelial growth factor (VEGF) production in hair follicles, boosting local angiogenesis and improving tissue blood supply — an effect demonstrated experimentally in animal models and partly confirmed in humans.
The net effect of these mechanisms is a prolonged anagen phase, premature 'awakening' of follicles sitting in telogen (resting phase), and enlargement of the follicles themselves — the miniaturized, thin hairs typical of androgenetic alopecia can gradually rebuild their diameter and growth-cycle length. That's why minoxidil is classified as a hair-growth stimulant, as opposed to finasteride, which primarily halts the progression of follicle miniaturization by blocking its hormonal cause.
It's also worth knowing that a large number of follicles shifting from telogen to anagen nearly simultaneously causes a characteristic clinical effect covered in the side-effects section below — the so-called shedding phase, often misread by new users as worsening, when it's actually a physiological sign that old telogen hairs are being pushed out by new, growing anagen hairs.
Conversion to active form
The enzyme sulfotransferase (SULT1A1) in the hair follicle and liver converts minoxidil into its active metabolite, minoxidil sulfate.
Potassium channel opening
Minoxidil sulfate opens K_ATP channels, hyperpolarizing the cell membrane in blood vessels and hair follicle cells.
Vasodilation and better blood flow
Widening of small scalp vessels increases blood, oxygen, and nutrient delivery to hair follicles.
Cell survival signaling
Activation of the ERK and Akt pathways, plus a shifted Bcl-2/Bax ratio, extends dermal papilla cell survival and delays the shift into catagen.
Anagen phase prolongation
Follicles stay longer in the growth (anagen) phase, increasing maximum hair length and density across the cycle.
Local angiogenesis
Increased VEGF production drives new small vessel formation around the follicle, supporting its nourishment over the longer term.
Evidence: strong — based on 4 studies in this database.
Benefits
Common myths
MythIf hair starts shedding more after starting minoxidil, that's a sign the drug is harming you and you should stop.
FactThis is the so-called shedding phase — a physiological hair-cycle synchronization response in which older telogen hairs are pushed out by new hairs entering anagen under the drug's influence. It usually resolves on its own within a few to several weeks and is actually a sign the drug is starting to work, not that it's causing harm.
MythMinoxidil works equally well for everyone who uses it.
FactTreatment response depends partly on the activity of the sulfotransferase enzyme (SULT1A1) in the follicle, which converts minoxidil into its active form — people with lower enzyme activity may respond more weakly to a standard dose, one reason behind so-called non-responders.
MythSince it's a hair-loss drug, it must work by affecting testosterone or DHT, like finasteride.
FactNot true — minoxidil works through a completely different, hormone-independent mechanism: it widens scalp blood vessels and extends the hair growth (anagen) phase. It doesn't lower DHT and doesn't meaningfully affect testosterone levels, setting it apart from 5-alpha-reductase inhibitors.
MythThe oral form of minoxidil can be safely bought and used on your own, without a prescription or medical supervision, just like the topical form.
FactThe oral form has a completely different, systemic risk profile than the topical one (fluid retention, tachycardia, possible interactions with blood pressure medication) and in Poland requires a prescription and individualized dosing by a doctor — not self-import or an online purchase.
Forms & variants
Minoxidil comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
2% topical solution
The first approved form, also cleared for women; a weaker effect than 5%, but also a lower irritation risk.
Best for: Women who prefer a lower concentration, or people with sensitive scalp skin
5% topical solution
The most commonly used form in men, giving significantly better regrowth than 2% in head-to-head trials, at a slightly higher risk of local irritation.
Best for: Men with androgenetic alopecia seeking maximum efficacy from the topical form
5% foam (propylene-glycol-free)
A formulation without propylene glycol, significantly less likely to cause scalp irritation and itching than the classic solution, with comparable efficacy.
Best for: People with a history of irritation from the solution, or who prefer a less sticky application
Low-dose oral minoxidil (LDOM)
Tablets at 0.625-5 mg/day, used off-label; more convenient application (no local irritation), but a different, systemic risk profile (hypertrichosis, swelling, tachycardia).
Best for: People who can't tolerate the topical form or struggle with daily application consistency, under medical supervision
Combination formulas with tretinoin
Minoxidil combined with a small dose of tretinoin to increase skin permeability and active ingredient absorption, studied in several smaller clinical trials.
Best for: People with a weaker response to the standard solution, under dermatological supervision due to higher irritation risk
For active people
Training regularly? Check your supplement profile.
Sleep, diet, training frequency, and recovery all matter. Answer a few questions and see which supplements might make the most sense for you.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
It's best studied and most effective for male androgenetic alopecia and female pattern hair loss (FPHL), especially in early and moderate stages where follicles still exist, even if miniaturized. It's less effective for complete, long-standing follicle loss and for scarring types of alopecia, where the follicle itself has been irreversibly destroyed.
That's the shedding phase, resulting from the drug synchronizing the hair growth cycle — older resting (telogen) hairs get pushed out by new hairs entering the growth (anagen) phase. It typically lasts 2 to 8 weeks and resolves on its own without needing to stop treatment.
Data from randomized head-to-head trials show broadly similar efficacy between low-dose oral minoxidil and the 5% topical form, with some differences depending on scalp area and oral dose. The oral form does carry a clearly higher risk of systemic side effects (hypertrichosis, swelling, tachycardia), which we cover in more depth in a separate article comparing both forms.
The drug's effect fully depends on continued treatment. After stopping, newly regrown, strengthened hair usually returns to the miniaturized state typical of untreated androgenetic alopecia within 3-6 months, with follicles reverting to the course they'd have followed without treatment.
Yes, this is common, well-documented clinical practice — the two drugs work through different, independent mechanisms (vasodilation and anagen prolongation versus DHT blockade), and combination therapy in clinical trials usually outperforms either drug used alone.
It's not standardly recommended during pregnancy or breastfeeding due to insufficient safety data, even though systemic absorption of the topical form is generally low. Any decision about use during this period should always be discussed with the physician managing the pregnancy.
The first visible signs of regrowth usually appear after 3-4 months of consistent use, with a full effect — assessable against baseline photos — typically visible after 6-12 months. Stopping early due to a lack of visible results is one of the most common reasons treatment fails.
Dosage & timing
Typical dose
Topical form: 1 ml of 5% solution or the equivalent foam dose, applied twice daily to dry scalp (women sometimes use 5% foam once daily or a 2% solution). Oral form (LDOM, off-label): typically 0.625-5 mg/day, most often 1.25-2.5 mg, individually dosed by a physician
Form
Topical solution or foam; tablets split for the oral form (compounding pharmacy preparation)
Dosing is informational and reflects the ranges used in the cited studies — it does not replace consulting a doctor or pharmacist.
Best times to take it
- Topical form: apply to a completely dry scalp, avoiding hair washing for about 4 hours afterward to allow absorption
- Consistency matters most — missing a few days isn't critical, but multi-week gaps lead to losing the effect and having to go through the shedding phase again
- The oral form is usually taken once daily in the morning, which for some patients reduces the risk of evening fluid retention and sleep disturbance
- The effect fully depends on continued treatment — stopping either form leads to losing newly regrown hair within 3-6 months
What to combine with
Good combinations
Testosterone — Minoxidil doesn't affect testosterone or DHT levels, so it's often combined with hormonal hair-loss treatments (like finasteride) without hormonal interaction concerns
Safety
Side effects & contraindications
Possible side effects
Irritation, redness, and scalp itching — the most common side effect of the topical form, partly linked to the propylene glycol in the solution (less common with foam, which doesn't contain it)
A temporary, intensified shedding phase in the first 2-8 weeks of treatment — a physiological hair-cycle synchronization response, not a sign treatment is failing
Unwanted hypertrichosis (excess hair growth) on the face and elsewhere on the body — rare with the topical form (around 2-4%), substantially more common with the oral form (anywhere from several to tens of percent, depending on dose)
With the oral form: fluid retention and swelling, especially around the ankles and face — one of the more common reasons for dose reduction or discontinuation
With the oral form: rapid heartbeat (tachycardia) and palpitations — usually mild but worth monitoring, especially at higher doses
Rarely: dizziness and blood pressure drops, more common with the oral form in people already taking antihypertensive medication
Rarely: allergic skin reactions (contact dermatitis) requiring discontinuation and dermatological consultation
Very rarely, reported in isolated case reports: pericardial effusion at very high oral doses (the kind used for hypertension, not hair loss) — the basis for caution in people with existing heart disease
Contraindications
Known hypersensitivity to minoxidil or any other ingredient in the preparation
Damaged, irritated, or infected scalp skin — applying the topical form to such skin increases systemic absorption and side-effect risk
Pregnancy and breastfeeding — due to insufficient safety data, despite the topical form's generally low systemic absorption
Significant, uncontrolled cardiovascular disease (especially with the oral form) — requires a cardiology evaluation before starting treatment
Pheochromocytoma — a classic contraindication for minoxidil in its original cardiology indication
Interactions
Other antihypertensive medications (especially with the oral form) — risk of exaggerated blood pressure drops
Topical retinoids (e.g. tretinoin) applied to the scalp — increase skin permeability and minoxidil absorption, which is sometimes used therapeutically but also raises side-effect risk
Potent topical corticosteroids — similarly increase absorption through a compromised skin barrier
Large amounts of alcohol with the oral form — may intensify blood pressure drops and dizziness
Is it worth taking?
Who it's for
- Men with early- to moderate-stage androgenetic alopecia, especially in the crown area (less effective where follicles are already completely lost in advanced frontal balding)
- Women with female pattern hair loss (FPHL), for whom finasteride isn't standard practice
- People looking for a treatment with no effect on androgenic hormones, e.g. out of concern about finasteride's sexual side effects
- People combining treatment with a 5-alpha-reductase inhibitor to maximize the effect through two different mechanisms
- People who can't tolerate the topical form (irritation, burdensome daily application) — candidates to discuss LDOM with a doctor
Not for
- Known hypersensitivity to minoxidil or any other ingredient in the preparation
- Damaged, irritated, or infected scalp skin — applying the topical form to such skin increases systemic absorption and side-effect risk
- Pregnancy and breastfeeding — due to insufficient safety data, despite the topical form's generally low systemic absorption
- Significant, uncontrolled cardiovascular disease (especially with the oral form) — requires a cardiology evaluation before starting treatment
- Pheochromocytoma — a classic contraindication for minoxidil in its original cardiology indication
Evidence
Worth knowing
Minoxidil was originally an oral drug for severe hypertension — its use for hair loss was discovered by accident, from the hypertrichosis side effect.
The 5% topical solution produced 45% more hair regrowth than the 2% solution in a clinical trial after 48 weeks of treatment.
The drug is a prodrug — only the sulfotransferase enzyme in the hair follicle converts it into active minoxidil sulfate, partly explaining why response varies between people.
Unlike finasteride, minoxidil doesn't meaningfully affect DHT or testosterone levels — it works through vasodilation and anagen-phase prolongation.
Studies
After 48 weeks of treatment, 5% topical minoxidil produced 45% more hair regrowth than the 2% solution, with the treatment response also appearing earlier in the higher-concentration group.
Olsen EA et al., Journal of the American Academy of Dermatology, 2002
A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men
Strong evidenceOlsen EA, Dunlap FE, Funicella T et al. · Journal of the American Academy of Dermatology · 2002
A 48-week, multicenter, double-blind, placebo-controlled randomized trial in 393 men (18-49) with androgenetic alopecia. 5% topical minoxidil was significantly more effective than 2% and placebo in non-vellus hair count, patient rating, and investigator-rated scalp coverage — producing 45% more regrowth than 2% at week 48, with an earlier treatment response. Itching and local irritation were more common in the 5% group.
View studyA randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss
Strong evidenceLucky AW, Piacquadio DJ, Ditre CM et al. · Journal of the American Academy of Dermatology · 2004
A 48-week RCT in 381 women with female pattern hair loss. Both 5% and 2% topical minoxidil were significantly more effective than placebo in non-vellus hair count and scalp-coverage ratings; 5% was statistically superior to 2% in patients' subjective benefit rating, with slightly more frequent local irritation.
View studyMinoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial
Strong evidenceRamos PM, Sinclair RD, Kasprzak M, Miot HA · Journal of the American Academy of Dermatology · 2020
A randomized trial comparing oral minoxidil 1 mg/day with topical 5% solution in women with female pattern hair loss. Both forms proved comparably effective in hair density after the treatment period, though hypertrichosis (unwanted facial and body hair growth) was significantly more common in the oral group.
View studySafety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients
Strong evidenceVañó-Galván S, Pirmez R, Hermosa-Gelbard A et al. · Journal of the American Academy of Dermatology · 2021
A retrospective, multicenter study of 1404 patients (67% women, mean age 43) treated with low-dose oral minoxidil for at least 3 months for various types of hair loss. The most common side effect was hypertrichosis (15.1%, a reason for discontinuation in 0.5% of patients). Systemic adverse effects were reported in 5.5% of patients (dizziness, fluid retention/swelling, tachycardia, headaches), with no life-threatening events observed.
View studySources & bibliography
- Olsen et al. 2002 — Journal of the American Academy of Dermatology
- Lucky et al. 2004 — Journal of the American Academy of Dermatology
- Ramos et al. 2020 — Journal of the American Academy of Dermatology
- Vañó-Galván et al. 2021 — Journal of the American Academy of Dermatology
- DermNet NZ — Minoxidil
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.
268 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna studied molecular biology at the University of Warsaw, then spent eight years after her PhD in a lab researching the mechanisms of cellular aging and autophagy. She stumbled into science journalism almost by accident — frustrated by how easily her field's findings get oversimplified in the media, she started a blog explaining the biology of aging in plain language. That blog became the seed of VitMode. Today Anna oversees the entire editorial process, holding every piece to the same rigor her old lab demanded: primary sources, methodology checks, and honesty about the limits of the evidence. Outside work, she's a dedicated boulderer.
196 publications on this site
Related entries
4.7Testosterone
The primary anabolic hormone — its natural level depends heavily on sleep, resistance training, body composition and fat mass.
3.6Scalp Mesotherapy
A treatment that involves injecting a mix of vitamins, minoxidil, growth factors, or other substances into the scalp — marketed in clinics as a modern alternative to 'boring' drops and pills. The catch: the umbrella term 'mesotherapy' covers literally any combination of ingredients, and the scientific evidence is far weaker and more inconsistent than clinic marketing suggests.
4.5Metformin
The most commonly prescribed drug for type 2 diabetes in the world — with a well-understood metabolic mechanism and an intensively studied, but still unproven, potential to slow aging.
4.5Tirzepatide
The first approved drug that simultaneously activates two different incretin receptors — GIP and GLP-1 — rather than just one, like older drugs in this class. In head-to-head trials it produced greater weight loss than semaglutide, at the cost of a very similar side-effect profile.
4.4Statins
The best-researched class of LDL-cholesterol-lowering drugs, with one of the largest evidence bases in all of cardiology — yet still surrounded by numerous, largely unfounded fears.
4.3Proton Pump Inhibitors (PPIs)
Among the most commonly prescribed drugs in the world, effectively suppressing stomach acid production — but increasingly used chronically for longer than clinical guidelines suggest.
Related articles
PoradnikiOral vs. Topical Minoxidil: What the Head-to-Head Trials Actually Show
Low-dose oral minoxidil (LDOM) is one of the fastest-growing trends in hair-loss treatment of the past few years — a convenient pill instead of a sticky solution applied twice a day. The catch: it's still an off-label use, with a completely different risk profile than the topical form. We look at what head-to-head comparative trials actually show, instead of relying on enthusiastic posts from hair-loss forums.
October 5, 2026
PoradnikiFinasteride and Dutasteride for Male Pattern Hair Loss: Efficacy, Side Effects, and the Post-Finasteride Syndrome Debate
Finasteride has been, for nearly three decades, the best-studied drug for male pattern hair loss, and dutasteride is often marketed as its stronger successor. Both block the enzyme that converts testosterone into DHT — and both carry a risk of sexual side effects that a small subset of patients describe as persisting even after stopping the drug. We check what large clinical trials and meta-analyses actually show — without downplaying the controversy around so-called post-finasteride syndrome, but also without overstating it.
September 4, 2026
PoradnikiCreatine and Hair Loss: Does the Supplement Really Raise DHT?
"Creatine causes baldness" is one of the most repeated warnings in gym culture — and it rests on exactly one study from 2009, which never measured hair loss at all. That study did show a real spike in DHT, the hormone responsible for pattern hair loss, up 56% after a week of creatine loading. The catch: nobody since has ever tested whether that DHT spike actually translates into real hair loss — and those are very different questions.
August 23, 2026
PoradnikiTestosterone and Hair Loss — Does TRT Speed Up Balding?
DHT, the androgen receptor, and hair follicle genetics: the full mechanism behind male pattern baldness in men on TRT, genetic testing, and an honest rundown of treatment options — from minoxidil to combining finasteride with testosterone therapy.
August 15, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.